Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double‐Blind, Placebo‐Controlled REGAIN, and Pooled EVOLVE‐1 and EVOLVE‐2 Studies

• Published in: Headache Vol. 60; no. 10; pp. 2202 - 2219
• Main Authors: Smitherman, Todd A., Tietjen, Gretchen E., Schuh, Kory, Skljarevski, Vladimir, Lipsius, Sarah, D’Souza, Deborah N., Pearlman, Eric M.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.11.2020; John Wiley and Sons Inc
• Subjects: Anxiety; comorbid; Comorbidity; Confidence intervals; depression; Double-blind studies; Evaluation; galcanezumab; Headache; Health services; Impairment; Medical history; Mental depression; Migraine; Monoclonal antibodies; Patients; Prevention; Research Submission; Research Submissions; Statistical analysis; Subgroups; comorbid; anxiety; migraine; depression; galcanezumab; prevention

Objective This post hoc analysis evaluated the efficacy of galcanezumab for the prevention of migraine in patients with and without comorbid anxiety and/or depression. Background Patients with migraine have a higher risk of anxiety and/or depression. Given the high prevalence of psychiatric symptoms...